[{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Ginkgo Biloba Extract","moa":"Sodium-dependent noradrenaline transporter; Phospholipase A2, membrane associated; Glycine receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Amine oxidase [flavin-containing] A; Nitric oxide synthase, inducible","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Ginkgo Biloba Extract

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Ginkgo Biloba Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 15, 2021

                          Lead Product(s) : Ginkgo Biloba Extract

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank